Merck & Co. will release its fourth-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

Merck is asking a Georgia court to dismiss a lawsuit tied to the former Albany pharmaceutical plant. The original complaint, ...

Merck & Co., Inc. (NYSE:MRK) is one of the best affordable healthcare stocks to buy now. Jefferies analyst Tycho Peterson ...

After a drawn-out litigation process, Merck & Co. seems to have finally washed its hands of more than a thousand lawsuits tied to its shingles vaccine Zostavax. Late last week, the U.S. Court of ...

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.

Merck is strong in cash and balance sheet and will have continued growth in their highest-margin product while being greatly ...

Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at ...

Overview of Merck & Co., Inc. operations, institutional ownership disclosures, pharmaceutical research activities, and index ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

On December 17, the US Food and Drug Administration moved to fast-track reviews of two experimental Merck & Co., Inc.

Merck is planning layoffs in Pennsylvania as part of a multi-year plan to wind down operations at a manufacturing plant in the state. The pharma giant will cut 163 jobs at its Cherokee manufacturing ...

In terms of liquidity and interest, the mean open interest for Merck & Co options trades today is 7184.25 with a total volume of 2,408.00.